About Us

Overview

• Our Mission
  Become a world-class RNAi biopharmaceutical innovator and serve patients in need worldwide

  
• Our Vision
  Realize full potential of RNAi technology
  Bring life-changing RNA medicines to reality

  

Leadership Team

• 
  Weimin Wang, Ph.D.

  

  Founder, Chief Executive Officer

  Dr. Weimin Wang is one of the industry's leading oligonucleotide chemists with 25+ years of research experiences in the field. Dr. Wang has been a key contributor to the RNAi therapeutics industry, with more than 70 scientific publications and patents related to RNAi. Before founding SanegeneBio, he served as the Head of Chemistry at Dicerna Pharmaceuticals (acquired by Novo Nordisk in 2021) where his team played a crucial role in developing Dicerna's liver-targeting GalXC technology, as well as extrahepatic delivery platform. Prior to joining Dicerna, Dr. Wang worked at Merck & Co. for 7 years following its acquisition of Sirna, where he developed one of the first lipid nanoparticle delivery platforms for nucleic acid therapeutics. Throughout his tenure at Sirna, Merck, and Dicerna, Dr. Wang has also evaluated over 500 external opportunities for nucleic acid drug discovery and delivery technology, as well as engaged in numerous significant collaborations including with Eli Lilly, Roche, Novo Nordisk, Boehringer Ingelheim, Alexion, etc.

• 
  Shiyu Wang, Ph.D.

  

  Co-Founder, Chief Scientific Officer

  Dr. Shiyu Wang received her Ph.D. in biochemistry from Penn State University. She has 15+ years of research experiences in siRNA and antisense oligonucleotides therapeutic development. Dr. Wang brings in her extensive industrial experience in molecular mechanism of oligonucleotide delivery, disease-causing genes identification, lead optimization, in vitro/in vivo pharmacology and assay development as well as hepatic/extrahepatic platform discovery. During her tenure at the Ionis Pharmaceutical Core Research Department and Dicerna Pharmaceuticals, Dr. Wang spearheaded numerous key preclinical studies using various disease models, led multidisciplinary teams advancing internal and external programs from target identification through late-stage development. Dr. Wang also managed numerous partnering projects including with Eli Lilly, Novo Nordisk, etc.

• 
  Marc Abrams, Ph.D.

  

  Chief Technology Officer and Head of US Operations

  Dr. Marc Abrams brings 20 years of leadership experience in oligonucleotide therapeutics and targeted delivery of genetic medicines, most recently as CSO of Carbon Biosciences and SVP of Discovery Research at Dicerna Pharmaceuticals (a Novo Nordisk company). He has also held several roles of increasing responsibility at Merck and Co., Inc., and has served on SanegeneBio's Scientific Advisory Board. 

• 
  Yuyan Jin, Ph.D.

  

  Senior Vice President of Clinical and Non-Clinical Development

  Dr. Yuyan Jin received her Ph.D. in Clinical Pharmacology from the University of Pittsburgh, served as a critical path fellow for two years at FDA, and completed a one-year global clinical scholar program at Harvard Medical School. Prior to joining SanegeneBio, Dr. Jin worked at Pfizer U.S. and Roche China Innovation Center for 15+ years, where she has led and engaged in preclinical research, early clinical development, and regulatory submissions for multiple innovative programs across neuroscience, oncology, infection, and immunology diseases. Dr. Jin has also contributed to multiple technical guidance in China as a member of scientific expert committee. She has numerous scientific publications and serves as a reviewer for several internationally recognized journals, such as <Clinical Pharmacology and Therapeutics>, <Journal of Clinical Pharmacology>, <British Journal of Clinical Pharmacology>.

• 
  Sibo Jiang, Ph.D.

  

  Vice President of CMC

  Dr. Sibo Jiang has 15+ years of experiences in oligonucleotide synthesis and downstream processing. Prior to joining SanegeneBio, Dr. Jiang has held several positions with increasing responsibility at the global leading oligonucleotide CDMO Nitto Denko Avecia. Under his leadership, the oligonucleotide team had completed 70+ development and production projects, supporting programs through preclinical to clinical and pre-commercial stages. Dr. Jiang brings in extensive industrial experiences, especially in the areas of process and analytical platform establishment, method development and optimization, process validation, raw material control, and GLP/GMP scale-up production.

• 
  Yang Liu, M.S., MBA.

  

  Vice President of Business Development

  Mr. Yang Liu has 15+ years of strategy and business development experiences in the pharmaceutical industry. He has successfully led or engaged in various types of transactions at different stages and across different therapeutic areas, including nearly 20 collaborations such as strategic investment, M&A, licensing in/out, co-development, funded research etc., with increasing responsibilities at Pfizer, Shire, Boehringer Ingelheim and Roche.

• 
  WEI R. CAMPBELL, J.D.

  

  Vice President of Intellectual Property

  WEI R. CAMPBELL is an intellectual property attorney with over 10 years of experience on a broad range of IP matters in biotechnology, pharmaceuticals, and life sciences, including patent strategy, global patent portfolio development and management, due diligence, IP litigation, transactional matters, trademarks, copyrights, trade secrets, and client counseling. Prior to joining SanegeneBio, she held important positions at biopharmaceutical companies such as Alnylam and BeiGene, leading the development of comprehensive global patent portfolios including oligonucleotide therapies and small molecule drugs, and optimizing global market exclusivity for commercial assets and pipeline programs.

Milestones